| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/26/2009 | US20090082467 Treatment of migraine headaches using antiestrogens |
| 03/26/2009 | US20090082465 Deuterium-enriched lisdexamfetamine |
| 03/26/2009 | US20090082462 Deuterium-enriched armodafinil |
| 03/26/2009 | US20090082461 Deuterium-enriched modafinil |
| 03/26/2009 | US20090082447 Pharmaceutical Compositions Containing Omega 3 Fatty Acids |
| 03/26/2009 | US20090082446 Use of Hydroxyoleic acid and related compounds in the manufacture of drugs |
| 03/26/2009 | US20090082440 Simple pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| 03/26/2009 | US20090082436 Deuterium-enriched rivastigmine |
| 03/26/2009 | US20090082434 Dihydrobenzofuranyl Alkanamine Derivatives and Methods for Using Same |
| 03/26/2009 | US20090082432 Deuterium-enriched ramelteon |
| 03/26/2009 | US20090082422 Deuterium-enriched levetiracetam |
| 03/26/2009 | US20090082401 Deuterium-enriched tiagabine |
| 03/26/2009 | US20090082396 5-aryl-4,5-dihydro-(1h)-pyrazolines as cannabinoid cb1 receptor agonists |
| 03/26/2009 | US20090082394 Tetrahydroisoquinoline Derivatives to Enhance Memory Function |
| 03/26/2009 | US20090082390 Piperidine compounds for use as orexin receptor antagonist |
| 03/26/2009 | US20090082388 Co-administration of pimavanserin with other agents |
| 03/26/2009 | US20090082384 Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| 03/26/2009 | US20090082382 Deuterium-enriched naltrexone |
| 03/26/2009 | US20090082373 Uses of 2-[piperidinyl]methyl-2, 3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one for providing an analgesic effect, anti-allergic effect and histamine H1 receptor antagonism effect |
| 03/26/2009 | US20090082369 Pyrrolo[2,3d]pyrimidine compositions and their use |
| 03/26/2009 | US20090082368 Methods of modulating neurotrophin-mediated activity |
| 03/26/2009 | US20090082362 Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure |
| 03/26/2009 | US20090082360 Use of tyrosine kinase inhibitors for treating CNS disorders |
| 03/26/2009 | US20090082359 5-pyridinone substituted indazoles |
| 03/26/2009 | US20090082358 Vanilloid receptor ligands and their use in treatments |
| 03/26/2009 | US20090082356 Pyrazine Derivatives and Use as P13k Inhibitors |
| 03/26/2009 | US20090082353 Treatment of epilepsy with non-imidazole alkylamines histamine h3-receptor ligands |
| 03/26/2009 | US20090082349 Thiazolones for use as pi3 kinase inhibitors |
| 03/26/2009 | US20090082346 Substituted Pyrrolo-Pyrazole Derivatives as Kinase Inhibitors |
| 03/26/2009 | US20090082345 Benzothiazole- and benzooxazole-4,7-dione, derivatives and their use as cdc25 phosphate inhibitors |
| 03/26/2009 | US20090082343 1,3-benzothiazinone derivatives and use thereof |
| 03/26/2009 | US20090082342 N-substituted piperidine derivatives as serotonin receptor agents |
| 03/26/2009 | US20090082341 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide FOR THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER |
| 03/26/2009 | US20090082340 3-substituted-5- and 6-aminoalkyl indole-2-carboxylic acid amides and related analogs as inhibitors of casein kinase i |
| 03/26/2009 | US20090082335 Deuterium-enriched oxcarbazepine |
| 03/26/2009 | US20090082334 Deuterium-enriched quetiapine |
| 03/26/2009 | US20090082308 histone deacetylase inhibitors; antiproliferative; antineoplastic; thioredoxin (TRX)-mediated diseases such as autoimmune, allergy, inflammatory diseases; and neurodegenerative diseases; hydroxamic acid moiety; 6-Carbamoylmethyl-benzo[b]thiophene-2-carboxylic acid (4-amino-1-phenyl-1H-pyrazol-3-yl)amide |
| 03/26/2009 | US20090082307 Culturing Lac Z-Y+ E. coli cell on glycerol and glucose in presence of lactose as exogenous precursor and isopropyl beta -D-thiogalactoside as inducer under conditions inducing the internalization according to a mechanism of active transport of exogenous precursor by cell and production of lactose |
| 03/26/2009 | US20090082271 Agents that reduce apoe-induced impairment of mitochondria and methods of use thereof |
| 03/26/2009 | US20090082265 Compositions and methods for treating diseases |
| 03/26/2009 | US20090081732 Antibodies to human il-1beta |
| 03/26/2009 | US20090081730 Activatable recombinant neurotoxins |
| 03/26/2009 | US20090081729 Compositions and Methods Comprising a Ligand of ChemerinR |
| 03/26/2009 | US20090081242 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| 03/26/2009 | US20090081238 Anti-notch1 NRR antibodies and methods using same |
| 03/26/2009 | US20090081234 administering a composition comprising an effective amount of at least one isolated mammalian anti-tumor necrosis factor (TNF) antibody comprising at least one variable region comprising SEQ ID NO:7 and 8 |
| 03/26/2009 | US20090081227 Promotong differentiation of neural stem cells to nerve cells for use in treating injury to central nerve system caused by brain infarction, hemorrhage and/or spinal cord injury |
| 03/26/2009 | US20090081204 Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits |
| 03/26/2009 | US20090081179 Method for reducing the severity of neurological disorders |
| 03/26/2009 | US20090081123 Pharmaceutical compounds |
| 03/26/2009 | CA2700332A1 N-substituted piperidine derivatives as serotonin receptor agents |
| 03/26/2009 | CA2700331A1 Co-administration of pimavanserin with other agents |
| 03/26/2009 | CA2700306A1 Chiral synthesis of diazepinoquinolines |
| 03/26/2009 | CA2699892A1 Pyridyl sulfonamides as modulators of ion channels |
| 03/26/2009 | CA2699689A1 Substituted nicotinamide compounds and their use in medicaments |
| 03/26/2009 | CA2699561A1 Methods of increasing sarcosine levels |
| 03/26/2009 | CA2699292A1 Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| 03/26/2009 | CA2698436A1 Tricyclic heterocyclic derivatives |
| 03/26/2009 | CA2696298A1 Modulators of cystic fibrosis transmembrane conductance regulator |
| 03/26/2009 | CA2693116A1 6-cycloamino-s-(pyridazin-4-yl)imidazo[1,2-b]-pyridazine and derivatives thereof preparation and therapeutic application thereof |
| 03/26/2009 | CA2691474A1 Cyanoisoquinoline |
| 03/25/2009 | EP2039779A1 Screening method |
| 03/25/2009 | EP2039694A1 CGRP receptor antagonists |
| 03/25/2009 | EP2039687A1 Therapeutic or prophylactic agent for multiple sclerosis |
| 03/25/2009 | EP2039681A1 Cycloalkene derivatives, process for production of the derivatives, and use of the same |
| 03/25/2009 | EP2039367A1 Prophylactic/therapeutic agent for neurodegenerative disease |
| 03/25/2009 | EP2039361A2 Use of immunomodulatory compounds |
| 03/25/2009 | EP2039360A1 Non-invasive direct delivery of opioids to the central nervous system |
| 03/25/2009 | EP2039359A1 Analgesic agent |
| 03/25/2009 | EP2039354A1 Compound having activity of blocking nmda receptor channel, and pharmaceutical agent using the same |
| 03/25/2009 | EP2038287A1 Spiro[benzopyran]or spiro[benzofuran]derivatives which inhibit the sigma receptor |
| 03/25/2009 | EP2038285A2 Adenosine a2a receptor antagonists |
| 03/25/2009 | EP2038281A2 Nicotinic agonists selective for the alpha7 receptor subtype, the process for the preparation thereof and pharmaceutical compositions therefrom |
| 03/25/2009 | EP2038280A2 Fused, tricyclic sulfonamide inhibitors of gamma secretase |
| 03/25/2009 | EP2038269A1 Substituted benzamide modulators of the histamine h3 receptor |
| 03/25/2009 | EP2038259A1 Benzimidazole derivatives, method for the production thereof, their use as fxr agonists and pharmaceutical preparations containing the same |
| 03/25/2009 | EP2037965A2 Pharmaceutical composition with synergistic anticonvulsant effect |
| 03/25/2009 | EP2037964A2 Combination preparations comprising bifeprunox and l-dopa |
| 03/25/2009 | EP2037928A2 Methods for treating atherosclerosis |
| 03/25/2009 | EP2037925A1 Combinations comprising 5ht6 modulators and cholinesterase inhibitors |
| 03/25/2009 | EP2037902A1 Cannabinoids for use in the treatment of neuropathic pain |
| 03/25/2009 | EP2037901A1 Use of pharmaceutical compositions comprising cannabigerol for the treatment of depression |
| 03/25/2009 | EP2037885A1 Low dose sublingual tablets of opioid analgesics and preparation process |
| 03/25/2009 | EP2037739A2 Benzyl-substituted quinolone m1 receptor positive allosteric modulators |
| 03/25/2009 | EP2000469A9 Acylaminopiperidine compound |
| 03/25/2009 | EP1697379B1 Spirocyclic cyclohexane derivatives |
| 03/25/2009 | EP1696931B1 Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| 03/25/2009 | EP1555265B1 7-phenyl pyrazolopyridine compounds |
| 03/25/2009 | EP1460999B1 Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof |
| 03/25/2009 | EP1353692B1 Methods and compositions for treatment of ocular neovascularization and neural injury |
| 03/25/2009 | EP1287035B1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 03/25/2009 | CN101395157A Pyrrazole derivatives as sigma receptors antagonists |
| 03/25/2009 | CN101395156A Imidazo[1,2-a]pyridin-3-yl-acetic acid hydrazides, processes for their preparation and pharmaceutical uses thereof |
| 03/25/2009 | CN101395152A Sigma receptor compounds |
| 03/25/2009 | CN101395142A 4-amino-1,5-substituted 1,5-dihydro-imidazol-2-ones |
| 03/25/2009 | CN101395139A Sigma receptor compounds |
| 03/25/2009 | CN101395138A Sigma receptor inhibitors |
| 03/25/2009 | CN101395133A Sigma receptor compounds |
| 03/25/2009 | CN101395104A An improved process for the preparation of armodafinil |
| 03/25/2009 | CN101394853A Use of pyrazolo[1,5a]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders |